Expression of MiR-30c and MiR-29b in Prostate Cancer and Its Diagnostic Significance

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Aug 22

PMID 30127906

Citations 13

Authors

Chuanan Zhu

Xiumei Hou

Jiabin Zhu

Chunxiao Jiang

Wei Wei

Affiliations

Soon will be listed here.

Abstract

This study aimed to investigate the expression of miR-30c and miR-29b in prostate cancer (PCa) and its clinical significance. The expression of miR-30c and miR-29b was detected by RT-qPCR in 187 cases of PCa and their adjacent tissues. Combined with clinical information, the correlation between the expression of miR-29b and miR-30c and the clinical features of PCa was analyzed, and ROC curve was plotted. The expression of miR-30c and miR-29b detected by RT-qPCR showed that the expression of miR-29b and miR-30c in PCa tissues was significantly lower than that in adjacent cancerous tissues (p<0.05). By comparing the expression and clinical data of miR-29b and miR-30c in the cancer tissues of PCa patients, it was observed that age, smoking, and TNM staging were not related to miR-29b and miR-30c expression (p>0.05), while lymph node metastasis, bone metastasis, and Gleason score were related to the expression of miR-29b and miR-30c (p<0.01). The ROC curve showed that miR-29b AUC, 0.924; 95% CI, 0.824-0.967, and miR-30c AUC, 0.944; 95% CI, 0.798-0.972. miR-30c and miR-29b are clinically relevant to PCa. In conclusion, detecting the expression of miR-30c and miR-29b not only can differentiate between PCa and paracancerous tissues, but it is also anticipated to become a new biomarker for the diagnosis of PCa.

Citing Articles

Extracellular Microvesicle MicroRNAs and Imaging Metrics Improve the Detection of Aggressive Prostate Cancer: A Pilot Study.

Avasthi K, Choi J, Glushko T, Manley B, Yu A, Park J Cancers (Basel). 2025; 17(5).

PMID: 40075682 PMC: 11898942. DOI: 10.3390/cancers17050835.

Extracellular microvesicle microRNAs, along with imaging metrics, improve detection of aggressive prostate cancer.

Avasthi K, Choi J, Glushko T, Manley B, Yu A, Pow-Sang J medRxiv. 2024; .

PMID: 39228742 PMC: 11370497. DOI: 10.1101/2024.08.23.24312491.

Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms.

Gujrati H, Ha S, Wang B Cancers (Basel). 2023; 15(12).

PMID: 37370750 PMC: 10296615. DOI: 10.3390/cancers15123140.

miR-29b Regulates Lung Cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/AKT Pathway.

Zhang H, Wang R, Deng Q Comput Math Methods Med. 2022; 2022:3110330.

PMID: 36003920 PMC: 9393195. DOI: 10.1155/2022/3110330.

miR-29b-3p inhibits 22Rv1 prostate cancer cell proliferation through the YWHAE/BCL-2 regulatory axis.

Zhao J, Ma X, Xu H Oncol Lett. 2022; 24(2):289.

PMID: 35928803 PMC: 9344263. DOI: 10.3892/ol.2022.13409.

References

Baade P, Youlden D, Cramb S, Dunn J, Gardiner R . Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int. 2013; 1(2):47-58. PMC: 3814115. DOI: 10.12954/PI.12014. View

Zhang J, Wang X, Wang Y, Peng R, Lin Z, Wang Y . Low expression of microRNA-30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein. Oncol Lett. 2017; 14(1):363-368. PMC: 5494817. DOI: 10.3892/ol.2017.6163. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Steele R, Mott J, Ray R . MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer. 2010; 1(4):381-387. PMC: 2908325. DOI: 10.1177/1947601910371978. View

Esfahani M, Ataei N, Panjehpour M . Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J Cancer Prev. 2015; 16(7):2601-11. DOI: 10.7314/apjcp.2015.16.7.2601. View

Ha M, Kim V . Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014; 15(8):509-24. DOI: 10.1038/nrm3838. View

Ferretti S, Patriarca S, Carbone A, Zanetti R . [TNM classification of malignant tumours, VII edition 2009. Changes and practical effects on cancer epidemiology]. Epidemiol Prev. 2010; 34(3):125-8. View

Nishikawa R, Goto Y, Kojima S, Enokida H, Chiyomaru T, Kinoshita T . Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. Int J Oncol. 2014; 45(1):401-10. DOI: 10.3892/ijo.2014.2437. View

Iorio M, Croce C . MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012; 4(3):143-59. PMC: 3376845. DOI: 10.1002/emmm.201100209. View

10.

Pokharel S, Patel N, Garg K, La Rosa F, Arangua P, Jones C . Multi-parametric MRI findings of transitional zone prostate cancers: correlation with 3-dimensional transperineal mapping biopsy. Abdom Imaging. 2014; 40(1):143-50. DOI: 10.1007/s00261-014-0199-5. View

11.

Carthew R . Gene regulation by microRNAs. Curr Opin Genet Dev. 2006; 16(2):203-8. DOI: 10.1016/j.gde.2006.02.012. View

12.

Thorstenson A, Garmo H, Adolfsson J, Bratt O . Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study. J Urol. 2016; 197(1):61-66. DOI: 10.1016/j.juro.2016.06.080. View

13.

Wolff J, Mason M . Drivers for change in the management of prostate cancer - guidelines and new treatment techniques. BJU Int. 2012; 109 Suppl 6:33-41. DOI: 10.1111/j.1464-410X.2012.11218.x. View

14.

Huang Z, Zhang L, Yi X, Yu X . Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma. Tumour Biol. 2015; 37(4):4359-65. DOI: 10.1007/s13277-015-4262-9. View

15.

Ling X, Han Z, Xia D, He H, Jiang F, Lin Z . MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Mol Biol Rep. 2014; 41(5):2779-88. DOI: 10.1007/s11033-014-3132-7. View

16.

Moltzahn F, Olshen A, Baehner L, Peek A, Fong L, Stoppler H . Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2010; 71(2):550-60. PMC: 3022112. DOI: 10.1158/0008-5472.CAN-10-1229. View

17.

White A, Joseph D, Rim S, Johnson C, Coleman M, Allemani C . Colon cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer. 2017; 123 Suppl 24:5014-5036. PMC: 6152891. DOI: 10.1002/cncr.31076. View

18.

Marantz P, Hall C, Derby C . Radical prostatectomy versus watchful waiting. N Engl J Med. 2005; 353(12):1298-300. View

19.

Sfanos K, Yegnasubramanian S, Nelson W, De Marzo A . The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol. 2017; 15(1):11-24. DOI: 10.1038/nrurol.2017.167. View